logo-loader
viewLexagene Holdings Inc

Full interview: Lexagene Develops technology to test for deadly mosquito borne diseases

Lexagene (CVE: LXG-OTCQB-LXXGF) Founder and CEO Dr jack Regan joined Steve Darling from Proactive Vancouver on Skype with news the company has used their proprietary technology to develop a detection system for the Eastern Equine Encephalitis or EEE.

Regan says that not only can they use the system to test for EEE more quickly but also can test for other deadly diseases including Ebola.

Quick facts: Lexagene Holdings Inc

Price: 0.51 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $36.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc named herein, including the promotion by the Company of Lexagene Holdings Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexagene takes part in beta testing it’s technology in...

Lexagene (LXG) CEO and Co-Founder Dr Jack Regan joined Steve Darling from Proactive Vancouver on Skye to discuss the beta testing Lexagene did with CDX Analytics for rapid pathogen detection in cannabis and hemp. Regan telling Proactive what the testing was looking for and the results as...

on 09/05/2019

2 min read